Metallo--lactamase producing Enterobacteriaceae are of grave clinical concern particularly as there are no Metallo--lactamase (MBL) inhibitors approved for clinical use. The discovery and development of MBL inhibitors to restore the efficacy of available β-lactams are thus imperative. We investigated a 
Introduction
-lactams are broad-spectrum antibiotics with relatively minimal toxicity, making them antibiotics of choice for many bacterial infections (1) . However, the surge in resistance to β-lactams in Gram-negative bacteria is affecting the management of infections worldwide(2). -lactams are rendered ineffective through different mechanisms, including reduced membrane permeability through porin down-regulation and efflux, target site modification, and most importantly, the production of β-lactamases, enzymes that hydrolyze β-lactams(3, 4).
Metallo--lactamases (MBLs) are Ambler class B β-lactamases with zinc ions at their active sites. The zinc ions orient a hydroxide nucleophile to attack the carbonyl on a β-lactam ring(5, 6). Sub-class B1
MBLs are the most clinically relevant among the class B MBLs. They possess a binuclear active site, which contains either one or two Zn (II) ions and hydrolyze all -lactam antibiotics in clinical use except monobactams (7) . MBLs such as New Delhi Metallo-beta-lactamase (NDM), Verona Integron-Borne Metallo-β-Lactamase (VIM) and Imipenemase (IMP) mediate high-level resistance to antibiotics in carbapenem-resistant Enterobacteriaceae (CRE) (8) . CRE have been identified across the globe, including in all African regions (9) (10) (11) and have been ranked as critical in the World Health Organization's Priority Pathogens List for the Research and Development of New Antibiotics (12) . It is therefore imperative to invest in the discovery and development of MBL inhibitors (MBLIs) for combination therapy with carbapenems.
Potential MBLIs investigated to date have shown substantial in vitro activity but cannot be used clinically due to the simultaneous inhibition of human metallo-enzymes or their cytotoxicity effects (13) (14) (15) . MBLIs such as aspergillomarasmine A (AMA) (14) , Ca-ethylenediaminetetraacetic acid (Ca-EDTA)(13), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (16) are the few non-toxic MBLIs identified to date and act by chelating the zinc ions(17).
Herein, we investigated the inhibitory activity of 1, 4, 7-triazacyclononane (TACN) against wellcharacterized sub-class B1 MBL-producing Enterobacteriaceae. TACN has a different chemical structure with the smallest molecular weight in the family of metal chelator series reported. We believe that exploring and understanding the mechanisms of biologically relevant chemical moieties is the surest way to find clinically potent MBL Inhibitors that will give a lasting solution to this global menace.
Results

Minimum inhibitory concentrations (MICs), minimal bactericidal concentrations (MBCs), and MIC/MBC ratio
TACN is a cyclic organic compound within the NOTA and DOTA series and derived from cyclononane by replacing three equidistant CH 2 groups with NH groups(18) ( Figure 1 ). It can be seen from the structures that TACN is unique from that of NOTA and DOTA (family of compounds) (Figure 1 ). The results revealed that this molecule (TACN) successfully restored the activity of MEM against characterized clinical isolates of carbapenem-resistant Enterobacteriaceae expressing acquired subclass B1 metallo-beta-carbapenemases and reference strains with MIC values as low as 0.03 mg/L shown in table 1 and 2. Also varying inhibitory concentrations of TACN considerably enhanced the efficacy of MEM against the MBL-producing bacteria (varying from 2 mg/L to 64 mg/L). The lowest concentration of TACN at which most of the MEM activity was restored was 8 mg/L (Table 1 and 2) .
Therefore, all subsequent experiments were conducted with a fixed concentration of 8 mg/L (6.25%) of TACN. None of the tested serine β-lactamases (SBLs) types (K. pneumonia OXA-48 and E. cloacae KPC-2) was affected by TACN, substantiating the substrate spectrum of this compound (Table 1) .
MBCs of MEM were determined in the presence of TACN at a fixed concentration, and the MBC/MIC ratio of the combination ranged from 1-to 4-fold against both reference and clinical CRE isolates used in this study, except two clinical isolates, which had 8x the MIC values (Table 2) . K. pneumoniae ATCC BAA 1706 and E. coli ATCC 25922 had no changes in their MIC values when challenged with MEM alone and MEM+TACN.
Serum effect on MIC
The MIC values of MEM-TACN combinations in the presence of 50% human serum varied from ±1-to 4-fold dilutions compared to that of MEM-TACN in the absence of serum indicating that the inhibition properties of the combination were not affected by the presence of human serum (Table 1) .
Synergistic effect of TACN and MEM on CRE reference strains
The synergy between TACN and MEM against CRE isolates was investigated. In most of the cases, the minimum concentrations of TACN alone required to inhibit the MBL-producing Enterobacteriaceae were ≥128 mg/L (Table 1) . MEM alone exhibited inhibitory concentrations of ≥8 mg/L, indicating carbapenem-resistant phenotype of these pathogens(19). Challenging these CREs with a combined regimen of MEM-TACN potentiated the effectiveness of MEM. The calculated FIC index of MEM-TACN was ≤0.5, indicating a synergistic effect (Table 1) .
Time-kill kinetics
The combination of MEM-TACN caused a considerable decrease in the CFU/mL relative to the initial bacterial density of approximately 10 6 CFU/mL over the increasing time points (0, 1, 2, 4, 6, 8 and 24 h) against the tested isolates at different concentrations of the MIC values evaluated in this study (1x, 4x, 8x MICs) (Figure 2) . A 10^-3-fold decrease in the CFU/ml was observed when cells were treated with MEM-TACN at 1x, 4x and 8x MICs at 4 h. The time-kill kinetics results indicated that the TACN-MEM combinations had bactericidal activity against the selected CRE isolates. MEM alone when challenged at concentrations of 4x and 8x the MICs no significant decrease was observed during the time interval of 24 h.
Cytotoxicity
The 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to measure TACN cytotoxicity (0 -1024 mg/L) in HepG2 cells after 24-hour exposure. A decrease in cell viability was associated with an increase in TACN concentration (Figure 3) , and the regression analysis yielded an IC 50 of 56 mg/L. However, this IC 50 of TACN was far higher than the fixed MIC value of 8 mg/L used in this study.
Enzymatic assays
TACN efficiently inhibited the activity of NDM-1 in a concentration-and time-dependent manner illustrated by Figure 4A 
Computational simulations
The fluctuations of enzyme-ligand complex and ligand-associated movements were analyzed to ascertain their structural stability and movements during the simulation. These movements, which ensure their functional reliability and working efficiency, are essential for functionality and existence inside the living system. The overall systems showed appreciable stability as depicted in Figure 6 . The root-mean-square deviation (RMSD) of the entire system complex remained stable during the course of simulation of 100 ns. To gain further understanding of the active-site residue interactions with the compounds, the simulated complexes were observed with LigPlot protein-ligand interaction software. It was observed that the ligand is attached with the active site residues in all complexes as shown in Figure 7 . For TACN, His250, Asp124 residues provided H-bonding capability while His122, Asn220 and Trp93 roof the hydrophobic active-site pocket. These residues are providing the hydrophobic surface area while maintaining H-bonding capability.
Discussion
This study evaluated the TACN-MEM combination against clinical and reference CRE isolates and identified TACN as a promising MBL inhibitor. The affinity of metal chelators for binding/sequestering metal ions(21) such as zinc at MBLs' active sites makes them potential inhibitors that can be developed for treating CRE infections. TACN is a metal chelating agent that exhibited no cytotoxic effect at effective concentrations.
We showed that TACN significantly reduced the MIC of MEM, reinstating the carbapenem's efficacy show considerable structural shifts, suggesting the stability of the enzyme structure and strength of ligand attachment inside the active site pocket. The binding free energy analysis showed that the intermolecular van der Waals and the electrostatic interaction were the forces driving both systems.
However, the total solvation energy (∆Gsol) was unfavorable for all the complexes. Even though hydrogen bonds between the ligand and receptors were observed using LigPlot and chimera (Figure 7) , their influences could not compensate for the substantial desolvation penalties during the interaction, thereby leading to the total solvation energy (∆Gsol). Similar results have been reported previously where inhibition was dominated by the van der Waals interactions (26, 27 ).
In conclusion, this study showed that TACN inhibits Class B1 MBL-producing CREs with minimal cytotoxic effect at effective concentrations. TACN successfully potentiated the antimicrobial properties of MEM as should thus be further investigated as an MBLI for clinical development, in combination with carbapenems. Molecular modeling and docking studies demonstrated the mechanistic pathway of TACN to inhibit NDM-1 and VIM-2 sustaining a stable enzyme-ligand complex with the caveat that this is only simulation of a prediction and not likely to represent the actual binding mode. In-depth analysis and optimization of the metal-chelating agent (TACN), employing a multidisciplinary research approach involving advanced computational simulations, biochemical, microbiological, bio-informatics are needed in order to provide more evidence. 
Bacterial isolates
Seventeen carbapenem-resistant Enterobacteriaceae reference isolates (comprising 15 metallo-betalactamases and two serine-beta-lactamases) obtained from France (Institut Pasteur de France) ( Table   1 )(28) and thirty-three clinical isolates of metallo-beta-lactamases obtained from Lancet laboratories (private sector, South Africa) were employed in this study (Table 2) (29) . Klebsiella pneumoniae ATCC BAA 1706 and Escherichia coli ATCC 25922 purchased from the American Type Culture Collection (ATCC) were susceptible reference strains used as quality control. All bacterial isolates were fully characterized in previous studies for their phenotypic and genotypic resistance profiles(28, 29). The isolates were sub-cultured twice from freezer stocks onto MHA plates and incubated at 37 °C before the experiments. All subsequent liquid subcultures were derived from colonies isolated from the agar plates and were grown in broth medium (CAMHB).
Methods
Minimum Inhibitory Concentrations (MICs), Minimum Bactericidal Concentrations (MBCs)
MICs/MBCs determinations were performed according to CLSI guidelines and protocols described by Keepers et al. (19, 30) . Briefly, two-fold dilutions of MEM and TACN, from 0.015 to 16 mg/L and 1 to 64 mg/L respectively, were made with CAMHB in 96-well microtiter plates using the checkerboard method (14) . A 0.5 McFarland-standardized bacterial inoculum was suspended into 200 l CAMHB in each microtiter well. The plates were then incubated for 18-22 h at 37°C under aerobic conditions. The MIC was determined as the lowest concentration at which there was no visible growth. Afterwards, an aliquot of 100 μL was taken from the MIC assay wells in which no visible growth was observed and inoculated onto MHA plates for MBC determination by incubating at 37 °C for 24 h. The MBC was determined as the lowest concentration of the test compound that resulted in a ≥99.9% decrease of the initial inoculum in the viable bacterial count on the agar plates. Control wells were filled with the amount of solvent(s) used in dissolving drug candidates, CAMHB and bacteria. Experiments were conducted in triplicate.
Serum effects on the MIC
The effects of serum on the MIC of TACN-MEM combination were performed according previously described method(31) and the above-mentioned MIC assay. In this assay, however, sterile-filtered serum from human male AB plasma was added to the broth (CAMHB) to prepare 50% human serum in the final culture broth. Reference CRE strains carrying different enzymes (NDM-1, NDM-4, VIM-1, IMP-1 and IMP-8) were used to conduct this experiment.
Synergistic activity
The Synergistic activity assay was used to describe the effect of compounds (TACN and MEM) working together. The synergistic effect between TACN and MEM was determined by the combination assay as 
Time-kill assays
Time Kill assays were to measure the quantitative kinetic kill model of TACN for the selected organisms and different time points. Time-kill kinetic studies were conducted referring to the previously reported methods, including those described by CLSI (19, 30). E. coli producing bla NDM-1 , E. coli carrying bla VIM-1 as well as E. cloacae producing bla IMP-1 were selected for this assay. Briefly, freshly prepared colonies were re-suspended in 10 mL CAMHB and incubated in an orbital shaking incubator (37°C, 180 rpm) for 1 to 2 h. Cultures were then adjusted to a 0.5 McFarland standard (approximately 1.5x 10 8 CFU/mL) and further diluted 1:20 in CAMHB so that the starting inoculum was approximately 1.5x 10 6 CFU/mL. MEM was added to the prepared bacterial suspensions at final concentrations corresponding to 1x, 4x or 8x the MIC of MEM while in combination with TACN at a fixed concentration of 8 mg/L. Also, the time-kill kinetic of the MEM 4x and 8x MIC without TACN was investigated. A growth control with no antibiotic was included in the assay. The initial bacterial load was determined from the growth control test tube instantly after dilution step and was recorded as the CFU count at time zero. The test tubes were incubated in an orbital shaking incubator at 37°C and 180 rpm, and bacterial cell viability counts were performed at 1, 2, 4, 6, 8 and 24 hours by removing 100 μL of the culture, diluting as appropriate, and plating on MHA. The agar plates were incubated at 37°C for at least 22 h. Colonies were counted, and the results were recorded as the number of CFU/mL. A ≥3-log 10 decrease within 24 hours in the number of CFU/mL was considered bactericidal. The assays were executed in triplicate.
Cytotoxicity Assay
HepG2 cells were maintained at 37 o C in 10% complete culture medium (CCM; Eagles minimum essential medium supplemented with fetal bovine serum, antibiotics and L-glutamine) until confluent. 
Enzymatic assays: Enzyme inhibition and inactivation kinetic parameters
The inhibitory effect of TACN was monitoredby observing the rate of hydrolysis of the chromogenic nitrocefin, using purified preparations of sub-class B1 MBL enzyme (NDM-1) obtained from Raybiotech The preliminary mode of inhibition of NDM-1 by TACN was also assessed using the β-lactamase inhibitor screening kit reagents. Briefly, 500 nM of purified NDM-1 was pre-incubated with 20 μM of TACN at 25°C for 20 min, followed by rapid dilution with the addition of 30μM of nitrocefin; after which, changes in absorbance were monitored at 490 nm for 30 min. Experiments were conducted in triplicate.
Molecular modelling
System preparation
The crystal structures (PDB ID: 3Q6X, and 5ACU) were retrieved from the RSCB Protein Data Bank (https://www.rcsb.org/pdb/). The missing residues were added using a graphical user interface of Chimera, a molecular modelling tool (34) . A ligand interaction map was generated using the web version of PoseView (35) .
Molecular Docking
Docking calculations were obtained using AutoDock Vina software (36) . Geister partial charges were assigned, and the AutoDock atom types were defined using the AutoDock graphical user interface supplied by MGL tools (37) . The docked conformations were generated using the Lamarckian genetic algorithm (LGA) (38) . The binding affinities calculated for each of the two structures (enzyme: inhibitor complexes) were expressed in kcal/mol. This technique has been validated in previous studies (39) . The grid box was defined using Autodock Vina with the grid parameters being X= 26, Y= 18 and Z= 20 for the dimensions and X= -2.502, Y= -5.255 and Z= 32.723 for the center grid box. After using Autodock Vina, the ten conformations with lowest binding energy were chosen for molecular docking.
Molecular dynamics simulation
Missing parameters for the ligand in the Cornell et al. force field were created (40) in the absence of available parameters. Optimization of the ligands was first performed at the HF/6-31G* level with the Gaussian 03 package. The restrained electrostatic potential (RESP) procedure(41) was used to calculate the partial atomic charges. General amber force GAFF(42) force field parameters and RESP partial charges were assigned using the ANTECHAMBER module in the Amber14 package. Hydrogen atoms of the proteins were added using the Leap module in Amber12. The standard AMBER force field for bioorganic systems (ff03) was used to define the enzyme parameters. Counter ions were added to neutralize the enzyme charge. The system was enveloped in a box of equilibrated TIP3P water molecules with 8 Å distance around the enzyme. Cubic periodic boundary conditions were imposed, and the long-range electrostatic interactions were treated with the particle-mesh Ewald method (43) implemented in Amber12 with a non-bonding cut-off distance of 10 Å.
Initial energy minimization, with a restraint potential of 2 kcal/mol Å 2 applied to the solute, was carried out using the steepest descent method in Amber12 for 1000 iterations followed by conjugate gradient protocol for 2000 steps. The entire system was then freely minimized for 1000 iterations. Harmonic restraints with force constants 5 kcal/mol Å 2 were applied to all solute atoms during the heating phase.
A canonical ensemble constant number (N), volume (V), and temperature (NVT) MD was carried out for 50 ps, during which the system was gradually annealed from 0 to 300 K using a Langevin thermostat with a coupling coefficient of 1/ps. Subsequently, the system was equilibrated at 300 K with a 2 fs time step for 100 ps while maintaining the force constants on the restrained solute. The SHAKE algorithm(44) was employed on all atoms covalently bonded to a hydrogen atom during equilibration and production runs. A production run was performed for 2 ns in an isothermal-isobaric (NPT) ensemble using a Berendsen barostat(45) with a target pressure of 1 bar and a pressure coupling constant of 2 ps with no restraints imposed. The coordinate file was saved every 1 ps, and the trajectory was analyzed every 1 ps using Ptraj module implemented in Amber14.
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